A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

被引：7

作者：

Bell-McGuinn, Katherine M. y

Brady, William E.

Schilder, Russell J.

Fracasso, Paula M.

Moore, Kathleen N.

Walker, Joan L.

Duska, Linda R.

Mathews, Cara Amanda

Chen, Alice

Shepherd, Stacie Peacock

Giranda, Vincent L.

Aghajanian, Carol

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[4] Thomas Jefferson Univ, Philadelphia, PA 19107 USA

[5] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA

[6] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[7] OUHSC, Stephenson Canc Ctr, Oklahoma City, OK USA

[8] Univ Virginia Hlth Syst, Charlottesville, VA USA

[9] Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA

[10] NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA

[11] AbbVie, N Chicago, IL USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.5507

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5507

引用

页数：1